Literature DB >> 22475285

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Peter Valent1, Gerald J Gleich, Andreas Reiter, Florence Roufosse, Peter F Weller, Andrzej Hellmann, Georgia Metzgeroth, Kristin M Leiferman, Michel Arock, Karl Sotlar, Joseph H Butterfield, Sabine Cerny-Reiterer, Matthias Mayerhofer, Peter Vandenberghe, Torsten Haferlach, Bruce S Bochner, Jason Gotlib, Hans-Peter Horny, Hans-Uwe Simon, Amy D Klion.   

Abstract

Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475285      PMCID: PMC3625626          DOI: 10.1586/ehm.11.81

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  177 in total

Review 1.  Origin, regulation and physiological function of intestinal oeosinophils.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

Review 2.  Hemopoietic progenitors and cytokines in allergic inflammation.

Authors:  J A Denburg
Journal:  Allergy       Date:  1998       Impact factor: 13.146

Review 3.  Systemic activation of basophils and eosinophils: markers and consequences.

Authors:  B S Bochner
Journal:  J Allergy Clin Immunol       Date:  2000-11       Impact factor: 10.793

4.  Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Authors:  Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter
Journal:  Br J Haematol       Date:  2008-10-17       Impact factor: 6.998

Review 5.  Expression and function of beta 1 integrins on human eosinophils.

Authors:  M C Seminario; B S Bochner
Journal:  Mem Inst Oswaldo Cruz       Date:  1997       Impact factor: 2.743

6.  Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially.

Authors:  Lisa A Spencer; Craig T Szela; Sandra A C Perez; Casey L Kirchhoffer; Josiane S Neves; Amy L Radke; Peter F Weller
Journal:  J Leukoc Biol       Date:  2008-10-07       Impact factor: 4.962

7.  Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.

Authors:  Srdan Verstovsek; Ayalew Tefferi; Hagop Kantarjian; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Pat Ault; Carlos Bueso-Ramos; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

8.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

9.  Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.

Authors:  Hiroyuki Nagase; Shu Okugawa; Yasuo Ota; Masao Yamaguchi; Hideyuki Tomizawa; Kouji Matsushima; Ken Ohta; Kazuhiko Yamamoto; Koichi Hirai
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

Review 10.  Cardiovascular manifestations of hypereosinophilic syndromes.

Authors:  Princess U Ogbogu; Douglas R Rosing; McDonald K Horne
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

View more
  42 in total

1.  Prediction of drug-induced eosinophilia adverse effect by using SVM and naïve Bayesian approaches.

Authors:  Hui Zhang; Peng Yu; Ming-Li Xiang; Xi-Bo Li; Wei-Bao Kong; Jun-Yi Ma; Jun-Long Wang; Jin-Ping Zhang; Ji Zhang
Journal:  Med Biol Eng Comput       Date:  2015-06-05       Impact factor: 2.602

Review 2.  Biologic therapies targeting eosinophils: current status and future prospects.

Authors:  Fanny Legrand; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

3.  Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD).

Authors:  Bruce S Bochner; Wendy Book; William W Busse; Joseph Butterfield; Glenn T Furuta; Gerald J Gleich; Amy D Klion; James J Lee; Kristin M Leiferman; Michael Minnicozzi; Redwan Moqbel; Marc E Rothenberg; Lawrence B Schwartz; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

Review 4.  Hypereosinophilia and seroconversion of rheumatoid arthritis.

Authors:  Rachel K Rosenstein; Richard S Panush; Neil Kramer; Elliot D Rosenstein
Journal:  Clin Rheumatol       Date:  2014-03-08       Impact factor: 2.980

5.  Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.

Authors:  Yoshimitsu Shimomura; Hayato Maruoka; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2016-12-20       Impact factor: 2.490

Review 6.  Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Authors:  Melanie C Dispenza; Bruce S Bochner
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

7.  Characterization of a mouse model of hypereosinophilia-associated heart disease.

Authors:  Daniel R Prows; Andrea Klingler; William J Gibbons; Shelli M Homan; Nives Zimmermann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-14       Impact factor: 4.733

8.  Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.

Authors:  Hanneke C Kluin-Nelemans; Andreas Reiter; Anja Illerhaus; Bjorn van Anrooij; Karin Hartmann; Lambertus F R Span; Aleksandra Gorska; Marek Niedoszytko; Magdalena Lange; Luigi Scaffidi; Roberta Zanotti; Patrizia Bonadonna; Cecelia Perkins; Chiara Elena; Luca Malcovati; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Alexander Zink; David Fuchs; Alex Kilbertus; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Dietger Niederwieser; Christine Breynaert; Judit Várkonyi; Vanessa Kennedy; Olivier Lortholary; Thilo Jakob; Olivier Hermine; Julien Rossignol; Michel Arock; Jason Gotlib; Peter Valent; Wolfgang R Sperr
Journal:  Leukemia       Date:  2019-11-18       Impact factor: 11.528

Review 9.  The eosinophil: For better or worse, in sickness and in health.

Authors:  Bruce S Bochner
Journal:  Ann Allergy Asthma Immunol       Date:  2018-02-27       Impact factor: 6.347

Review 10.  Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors:  Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal:  Antioxidants (Basel)       Date:  2021-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.